Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC

Recruiting Early Phase 1 Interventional Study
Leukemia Inborn Errors of Metabolism Bone Marrow Failure Syndromes Immunodeficiencies Immunodysregulation Polyendocrinopathy Enteropathy X-linked Syndrome
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
Up to 30
Sex
Any
Trial phase
Early Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
100 (estimated)
Sponsor
Children's Hospital of Philadelphia · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of this protocol is to expand access for patients who lack a fully HLA (Human leukocyte antigen) matched sibling donor and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-threatening disease for which HSCT is indicated. These patients are not eligible for other Children's Hospital of Philadelphia IRB approved p…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Patients who lack a fully HLA matched sibling and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT) but are not deemed suitable candidates per their treating clinical team for current open institutional protocols using ClinMACs device for CD3+/CD19+ …
Contacts

Megan Atkinson

215-590-2820

cttsbmtintake@chop.edu

CONTACT

Patricia Hankins, BSN, RN, CCRC

215-590-5168

hankinsp@chop.edu

CONTACT